What's Happening?
OneOncology, a physician-led platform, along with the OneOncology Research Network (OneR), is set to present a wide array of scientific data at the 2025 American Society of Hematology (ASH) Annual Meeting. The presentations will include 25 scientific abstracts
covering various hematologic malignancies such as lymphoma, leukemia, and multiple myeloma. The research highlights the role of community-based investigators in advancing blood cancer research, showcasing innovations in targeted therapies, bispecific antibodies, and CAR-T therapies. The studies emphasize the importance of community practices in expanding access to cutting-edge treatments and clinical trials.
Why It's Important?
The participation of OneOncology and OneR in the ASH Annual Meeting underscores the critical role of community-based research in the field of hematology. By presenting a broad portfolio of data, these organizations highlight the potential for community practices to contribute significantly to medical research and innovation. This approach not only accelerates the development of new therapies but also ensures that patients in diverse settings have access to the latest treatments. The focus on bispecific antibodies and CAR-T therapies is particularly noteworthy, as these represent some of the most promising advancements in cancer treatment, offering hope for improved outcomes in aggressive and high-risk patient populations.
What's Next?
Following the ASH Annual Meeting, OneOncology and OneR are likely to continue their efforts in expanding research capabilities and collaborations. The insights gained from the meeting could lead to new partnerships and initiatives aimed at further integrating community practices into the broader research landscape. Additionally, the data presented may inform future clinical guidelines and treatment protocols, potentially influencing the standard of care for hematologic malignancies. As these organizations continue to push the boundaries of cancer research, they may also explore opportunities to expand their research networks and increase patient participation in clinical trials.
